Related Experiment Video

Updated: Jun 15, 2026

Combined Near-infrared Fluorescent Imaging and Micro-computed Tomography for Directly Visualizing Cerebral Thromboemboli
13:10

Combined Near-infrared Fluorescent Imaging and Micro-computed Tomography for Directly Visualizing Cerebral Thromboemboli

Published on: September 25, 2016

Tirofiban for myocardial infarction

Yahya B Juwana1, Harry Suryapranata, Jan Paul Ottervanger

  • 1Hospital Cinere, Cardiovascular Center, Jakarta, Indonesia.

Expert Opinion on Pharmacotherapy
|March 10, 2010
PubMed

Insights

Tirofiban effectively treats myocardial infarction by inhibiting platelet aggregation. This glycoprotein IIb/IIIa receptor inhibitor offers a favorable safety profile with low bleeding risk, making it a valuable option for specific patient groups.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Platelet aggregation inhibition is crucial for managing coronary artery disease.
  • Myocardial infarction (MI) treatment benefits from antiplatelet therapies.

Purpose of the Study:

  • To review the efficacy and safety of tirofiban in patients with ST-elevation MI (STEMI) and non-ST-elevation MI (NSTEMI).
  • To evaluate different dosing regimens and identify optimal patient populations for tirofiban use.

Main Methods:

  • Review of studies on tirofiban in STEMI and NSTEMI patients.
  • Analysis of various tirofiban dosage regimens (low, intermediate, high).

Main Results:

  • Tirofiban, a glycoprotein IIb/IIIa inhibitor, has a faster reversal of action than abciximab.
  • High-dose tirofiban may benefit STEMI patients undergoing primary percutaneous coronary intervention (PCI).
  • Tirofiban is indicated for NSTEMI patients with ongoing ischemia or dynamic ECG changes undergoing PCI, but not for those treated with thrombolysis.
  • Serious bleeding and thrombocytopenia risks are low.

Conclusions:

  • Tirofiban is an effective treatment for myocardial infarction.
  • Tirofiban demonstrates an acceptable safety profile for MI management.
Abstract

More Related Videos

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis10:26

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis

Published on: June 2, 2015

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...